ABSTRACT
Abstract The COVID-19 pandemic puts the healthcare systems at risk due to the still uncertain operational and financial impacts of it. The difficult economic conditions of the population also call for more attention from government officials to define strategies that guarantee access to health services and products. Maintaining the supply chain of pharmaceutical products is not only paramount to cover the immediate medical response but will be fundamental to reducing disruption of the healthcare system. Increasing drug prices during the pandemic is definitely not a strategy that contributes to access. In this sense, this commentary presents a criticism of a decision by the Brazilian government that may impact the availability in health services and the population's access to medicines necessary for the maintenance of life.
ABSTRACT
OBJECTIVE:To provide reference for setting reasonable medicines insurance payment price in China.METHODS:We retrieved and analyzed academic articles formally published at home and abroad,official websites and government documents,summarized.medicines insurance payment pricing mechanism as well as fair solutions to high-cost medicines,so as to put forward the suggestions to formulate reasonable medicines pricing policy in China.RESULTS&CONCLUSIONS:The international medicines payment prices are usually determined by internal reference pricing method,incremental cost-effectiveness evaluation method and external reference pricing method.The sustainable and fair accessibility of high-cost medicines are promoted by fair medicines pricing program,medicines patent pool,open source medicines discovery znitiative and so on.After the goal of universal health care has been achieved in china,reasonable medical insurance payment price should be explored and formulated.It is necessary to adopt,intemal reference pricing method to determine the payment standard of completitive eneric products,external reference pricing method or incremental cost-effectiveness evaluation method to determine the reference price for price negotiation of the innovative patented medicines;the concept of fair pricing for high-cost medicines.
ABSTRACT
Objective:This paper aims to analyze the impacts of medicine centralized bidding and purchasing policy based on the relationship between the bid winners and the bidden prices. Methods: A data collection method was used to collect data from medicine centralized bidding and purchasing policy in 31 provinces and OLS method has been employed to analyze impacts of the number of bid winners on the medicine prices. Results:The results showed a positive correlation between the number of bid winners and the bidden prices, which was a counter-intuitive appeal. In the group of non-essential medicines, the number of bid winners had a stronger impact on the bidden prices than in the group of essential medicines. Conclusions:The current medicine centralized bidding and purchasing policy does not achieve the expected objective and needs to be further improved.